石英股份（603688）公告，2024年营业收入12.1亿元，同比减少83.15%。归属于上市公司股东的净利润 3.34亿元，同比减少93.38%。基本每股收益0.62元／股，同比减少93.33%。公司2024年年度拟以实施权 益分派股权登记日登记的总股本(扣除股份回购专户内股票数量)为基数，向全体股东每10股派发现金红 利1.9元(含税)，不转增股本，不送红股，剩余未分配利润结转以后年度分配。 ...

前十大流通股东累计持有： 28649.35万股，累计占流通股比： 54.63%，较上期变化： -394.55万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 徐善水 | 21530.53 | 41.05 | 不变 | | 唐红军 | 1211.23 | 2.31 | 416.14 | | 姚发征 | 1050.19 | 2.00 | -11.83 | | 孙志松 | 963.99 | 1.84 | -113.60 | | 余永恒 | 922.25 | 1.76 | -341.99 | | 张亚 | 880.03 | 1.68 | 新进 | | 杨二果 | 625.10 | 1.19 | -371.35 | | 严书诚 | 573.58 | 1.09 | 10.68 | | 高源 | 470.00 | 0.90 | 新进 | | 朱向阳 | 422.45 | 0.81 | 新进 | | | 较上个报告期退出前十大股东有 | | | | 杨立新 | 927.07 | 1.77 | 退出 | | 张鑫良 | 442.31 ...

宇通客车（600066）公告，2025年第一季度营收为64.18亿元，同比下降3.00%；净利润为7.55亿元，同 比增长14.91%。 ...

兖矿能源（600188）公告，2025年第一季度营业收入为303.12亿元，同比下降23.53%；净利润为27.1亿 元，同比下降27.89%。 ...

Core Viewpoint - China Shenhua (601088) reported a decline in both revenue and net profit for the first quarter of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company's operating revenue for Q1 2025 was 69.585 billion yuan, representing a year-on-year decrease of 21.1% [1] - The net profit for the same period was 11.949 billion yuan, showing a year-on-year decline of 18.0% [1]

宝信软件（600845）公告，2025年第一季度营收为25.38亿元，同比下降25.16%；净利润为4.45亿元， 同比下降24.60%。 ...

神州信息（000555）公告，2025年第一季度营业收入21.6亿元，同比增长22.13%。净亏损9294.26万 元，去年同期净亏损5645.69万元。 ...

金宏气体公告，2025年第一季度营收为6.23亿元，同比增长5.62%；净利润为4400.32万元，同比下降 42.47%。 ...

Core Viewpoint - The recent financial report of Palin Biotech (000403) indicates a significant decline in both revenue and net profit for Q1 2025 compared to the same period in 2024, raising concerns about the company's financial health and operational efficiency [1]. Financial Performance - Total revenue for Q1 2025 was 375 million yuan, a decrease of 14.0% year-on-year [1]. - Net profit attributable to shareholders for Q1 2025 was 89.09 million yuan, down 26.95% from the previous year [1]. - The gross profit margin fell to 48.06%, a decline of 6.53% year-on-year [1]. - The net profit margin decreased to 23.74%, down 15.14% compared to the same period last year [1]. - Total expenses (selling, administrative, and financial) amounted to 67.59 million yuan, representing 18.04% of total revenue, an increase of 30.03% year-on-year [1]. Key Financial Ratios - Return on Invested Capital (ROIC) for the previous year was 8.42%, indicating average capital returns [3]. - The net profit margin for the previous year was 28.07%, suggesting high added value in products or services [3]. Shareholder Information - The company has raised a total of 5.241 billion yuan since its listing and has distributed 432 million yuan in dividends, resulting in a dividend-to-financing ratio of 0.08 [3]. - Analysts project that the company's performance for 2025 will reach 887 million yuan, with an average earnings per share of 1.21 yuan [3]. Fund Holdings - The largest fund holding Palin Biotech is the Huazhang Select Mixed Fund, which has reduced its holdings recently [4]. - Other funds, such as E Fund Balanced Growth and E Fund Kexiang Mixed, have maintained or increased their positions in the company [4].

拉卡拉（300773）公告，2024年营业收入57.59亿元，同比下降2.96%。归属于上市公司股东的净利润 3.51亿元，同比下降23.26%。公司拟向全体股东每10股派发现金红利2元(含税)，送红股0股(含税)，以 资本公积金向全体股东每10股转增0股。 ...